Chengdu Zeling Biomedical Technology Co. Ltd. has disclosed NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, inflammatory, autoimmune, cardiovascular, renal, gastrointestinal, respiratory and neurological disorders.
Claudin-6 (CLDN6) is a tight junction protein that has been found to be up-regulated in around 20 different types of cancer, among them ovarian, endometrial and germ cell tumors. Conventional T-cell engagers (TCEs), although effective, may be improved with costimulation to overcome T-cell exhaustion due to CDE3 stimulation alone.
Avacta Group plc has expanded its pipeline of Precision-enabled drug conjugates with the addition of two novel preclinical oncology assets, AVA-6103 and AVA-7100. The company’s peptide-drug conjugates (PDCs) comprise a payload linked to the Precision peptide, which is cleaved only within the tumor by the action of fibroblast activation protein (FAP).
Glioblastoma multiforme (GBM) recurs in most patients despite the aggressive therapies they receive. Novel advances allow the development of targeted therapies to treat tumors of the brain. Researchers from the Johns Hopkins School of Medicine have applied bioinformatics plus forward thinking on microRNA biology to advance targeted therapies for GBM.
Genetic Intelligence Inc. has described compounds acting as IL-2 expression or activity modulators reported to be useful for the treatment of cancer, infections, autoimmune diseases and inflammatory disorders.
Ventus Therapeutics US Inc. has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, metabolic diseases, autoimmune diseases, and liver, renal, respiratory, cardiovascular and inflammatory disorders, among others.
Incyte Corp. has identified tyrosine-protein kinase JAK2 (V617F mutant) inhibitors reported to be useful for the treatment of cancer, hypereosinophilic syndrome, systemic mastocytosis and essential thrombocythemia, among others.
Insilico Medicine Inc. has synthesized fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer.
Shandong New Time Pharmaceutical Co. Ltd. has disclosed compounds acting as Bruton tyrosine kinase (BTK) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.
Atavistik Bio Inc. has nominated an orally bioavailable selective allosteric AKT1 E17K inhibitor, ATV-1601, as a development candidate for AKT1 E17K-driven cancers.
RSS
